RE: StrugglesI defintely agree, this company is not an attractive buy right now because they have no solid cash creators in the market. Sure they have some prospects in phase 1 testing, but they have a lot further to go before they can consider marketing these products, and even $211 million in cash can be depleted quickly, especially when you have to incur costs of inevitable problems during testing, as well as when you are losing $27 million every 3 months. This company does not seem to have much of value to offer investors, and if the FDA decides to deny them approval of one of their new drugs, I can almost guarentee a new 52 week low.